Dubé, Marie-Pierre
Lemaçon, Audrey
Barhdadi, Amina
Lemieux Perreault, Louis-Philippe
Oussaïd, Essaïd
Asselin, Géraldine
Provost, Sylvie
Sun, Maxine
Sandoval, Johanna
Legault, Marc-André
Mongrain, Ian
Dubois, Anick
Valois, Diane
Dedelis, Emma
Lousky, Jennifer
Choi, Julie
Goulet, Elisabeth
Savard, Christiane
Chicoine, Lea-Mei
Cossette, Mariève
Chabot-Blanchet, Malorie
Guertin, Marie-Claude
de Denus, Simon
Bouabdallaoui, Nadia
Marchand, Richard
Bassevitch, Zohar
Nozza, Anna
Gaudet, Daniel
L’Allier, Philippe L.
Hussin, Julie
Boivin, Guy
Busseuil, David
Tardif, Jean-Claude
Funding for this research was provided by:
Philanthropist donations to the Montreal Heart Institute Foundation
The Government of Quebec
Bill and Melinda Gates Foundation
Article History
Received: 2 March 2021
Accepted: 11 May 2021
First Online: 25 May 2021
Competing interests
: MPD reports personal fees and minor equity interest from Dalcor Pharmaceuticals and personal fees from GlaxoSmithKline, other from AstraZeneca, Pfizer, Servier, Sanofi. MPD and JCT have a patent “Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events” issued to Dalcor, no royalties received, a patent “Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent” issued to Dalcor, no royalties received, and a patent “Methods for using low dose colchicine after myocardial infarction” with royalties paid to the Montreal Heart Institute. JCT reports grants from the Government of Quebec, the Montreal Heart Institute Foundation, the Bill and Melinda Gates Foundation, Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Pfizer, RegenXBio and Sanofi; personal fees from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pfizer, Pharmascience, Sanofi and Servier; and minor equity interest from Dalcor Pharmaceuticals. In addition, JCT’s institution has submitted a patent “Methods of treating a coronavirus infection using Colchicine” pending and a patent “Early administration of low-dose colchicine after myocardial infarction” pending. JCT has waived his rights in all patents related to colchicine and does not stand to benefit financially if colchicine becomes used as a treatment for COVID-19. NB reports personal fees from AstraZeneca outside of the present work. SdD was supported through grants from AstraZeneca, Pfizer, Roche Molecular Science, Dalcor Pharmaceuticals outside of the present work. JH is funded by an IVADO COVID-19 fast response grant with co-applicant MPD and JCT (CVD19-030). Other authors have nothing to declare.